US Supreme Court: No Six-Month Wait for Biosimilars After FDA Approval
By Zachary Brennan -
Published 12 June 2017
The US Supreme Court on Monday ruled unanimously that biosimilar companies will not have to wait an additional six months after US Food and Drug Administration (FDA) approval before launching their new biosimilars.
Categories: News, US, DOJ, FDA, Biologics and biotechnology, Business and Leadership, Government affairs, Regulatory intelligence, Regulatory strategy
Tags: Supreme Court of the United States, SCOTUS, biosimilars, patent dance